SIS Shulov - Innovative Science Ltd is an advanced clinical-stage biopharmaceutical company that specializes in developing New Chemical Entities (NCE's) for therapeutic purposes. Their focus is on creating innovative solutions for anti-inflammatory, anti-viral, and analgesic agents. The brand's flagship products are ZEP-3 and ZEP-4, which are short synthetic peptides with unique biological activity and powerful therapeutic use across a wide range of clinical indications.

SIS has successfully completed a Phase II clinical study for Herpes Labialis (Cold sores), demonstrating highly encouraging results in terms of time to healing, time to relief, and a significant decrease in Pain Intensity. They have also conducted a Phase I clinical study with the ZEP-3 compound, which showed excellent tolerability, safety, and an established skin pharmacokinetic profile. This makes it suitable for treating various indications, including Atopic Dermatitis, Burns, Psoriasis, and Herpes Zoster.

SIS is currently conducting a Phase II clinical study for Atopic Dermatitis (AD) and has initiated Phase I/II studies for Lung Inflammation and Burns. Furthermore, the brand is actively developing new clinical indications, such as Herpes Zoster, Genital Herpes, Occular Herpes, and Psoriasis. Contact SIS Shulov - Innovative Science Ltd to learn more about their groundbreaking research and cutting-edge solutions in the field of biopharmaceuticals